#United States #New York #Securities #Rosen Law Firm #ADMA Biologics

Rosen Law Firm's Investigation into ADMA Biologics

The Rosen Law Firm, a global legal firm dedicated to the rights of investors, has initiated an investigation concerning ADMA Biologics, Inc. (NASDAQ: ADMA). This inquiry is in light of recent allegations asserting that the company may have disseminated materially misleading information regarding its business, which could have significant ramifications for its shareholders. The firm is particularly focused on potential securities claims arising from these allegations, urging affected investors to inquire about their rights.

Background of Allegations

On March 24, 2026, a revealing article on Investing.com highlighted a dramatic decline in ADMA Biologics' shares following claims made by the short seller Culper Research. The report accused ADMA of engaging in "channel stuffing"—a practice wherein a company inflates its revenue figures by pushing excess products onto distributers—resulting in allegations that the company had misled investors about its revenue growth. Following this report, ADMA Biologics experienced a staggering 16.6% drop in its stock price, raising serious concerns among investors.

Potential Class Action

Shareholders who purchased securities in ADMA Biologics are being encouraged to participate in a class action lawsuit aimed at recovering losses suffered due to the alleged misleading practices by the company. Through a contingency fee arrangement, investors may pursue these claims without upfront costs, allowing them to seek compensation while mitigating financial risks.

To join this prospective class action, interested parties can visit the Rosen Law Firm's dedicated webpage or reach out directly via phone or email. This outreach ensures that those impacted can easily access resources and guidance through the legal process.

Why Choose Rosen Law Firm?

Rosen Law Firm emphasizes the importance of choosing a qualified law firm with a proven track record in handling securities class actions. Many firms that issue notices lack the requisite experience, resources, or recognition in the field. Rosen’s prominence is evident as it has secured notable settlements, including achieving the largest ever securities class action against a Chinese firm. The firm has consistently been ranked highly for its performance in this realm, recovering substantial amounts for its clients.

In 2019 alone, Rosen Law Firm successfully recovered over $438 million for investors, demonstrating its commitment to fighting for shareholder rights. Founding partner Laurence Rosen has garnered accolades, including being named a Titan of the Plaintiffs' Bar by Law360, reinforcing the firm’s reputation among investors and industry professionals alike.

Conclusion

For any investor in ADMA Biologics concerned about their financial well-being following these allegations, reaching out to the Rosen Law Firm could provide essential support. As the investigation continues, updates and further developments will be shared through various social media channels, including LinkedIn, Twitter, and Facebook. With a dedicated approach to investor rights, Rosen Law Firm stands ready to support individuals seeking justice and recovery in this challenging situation.